Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks
Year: 2023
Type: article
Abstract: Clinical outcomes for many childhood brain tumours remain poor, despite our increasing understanding of the underlying disease biology. Advances in molecular diagnostics have refined our ability to classify tumour types and subtypes, and efforts are underway across multiple international paediatric neuro-oncology consortia to take novel biological insights in the worst prognosis entities into innovative clinical trials. Whilst for the first time we are designing such studies on the basis of disease-specific biological data, the levels of preclincial evidence in appropriate model systems on which these trials are initiated is still widely variable. We have considered these issues between CONNECT, PNOC and ITCC-Brain, and developed a framework in which we can assess novel concepts being brought forward for possible clinical translation. Whilst not intended to be proscriptive for every possible circumstance, these criteria provide a basis for self-assessment of evidence by laboratory scientists, and a platform for discussion and rational decision-making prior to moving forward clinically.
Source: Frontiers in Oncology
Institutions: Institute of Cancer Research, University College London, Nationwide Children's Hospital, The Ohio State University, Great Ormond Street Hospital, University of California, San Francisco, Children's Hospital of Philadelphia, Université Paris Cité, Institut Curie, German Cancer Research Center, Hopp Children's Cancer Center Heidelberg, University of Zurich
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,295
Funder: Brain Tumour Charity
Awards: G2581612258, G4935959465
OpenAlex ID: W4362607181
